YTYibo Tang

Yibo Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yibo Tang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Shuyong Sun

    School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China

    3 shared publications
  • Yan Liao

    School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China

    3 shared publications
  • Zhenquan Liu

    School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China

    3 shared publications
  • Changhua Shi

    School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China

    2 shared publications
  • Cong Gai

    School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China

    2 shared publications
  • Huiming Qi

    School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China

    2 shared publications

Latest Publications

  • Open Access

    Cordyceps Polysaccharides Attenuate Experimental Ischemic Stroke Injury: Association with IL-17/NF-κB Signaling

    by Huizhang Wang, Yifan Chen, Yang Jiang, Yan Liao, Saiwen Xi, Xia Li, Huiming Qi, Yihui Ma, Yutong Li, Mujie Fang, et al.

    Cordyceps polysaccharides (CSP) have shown protective potential in ischemic stroke, but their central inflammatory mechanisms remain unclear. This study examined whether the effects of CSP are associated with interleukin-17 (IL-17)/nuclear factor kappa B (NF-κB)-related signaling. Publicly available human transcriptomic datasets were integrated and analyzed to identify inflammation-related pathways in ischemic stroke, and a public mouse middle cerebral artery occlusion (MCAO) single-cell RNA sequencing (RNA-seq) dataset was analyzed to identify relevant brain cell populations. IL-17 receptor A (IL-17RA) knockdown was performed in oxygen–glucose deprivation (OGD)-exposed SH-SY5Y cells. The effects of CSP were further evaluated in MCAO rats and OGD-exposed BV-2 cells. Bioinformatics analyses showed enrichment of IL-17 and NF-κB signaling in ischemic stroke datasets, and single-cell module-score analysis showed that microglia exhibited the largest MCAO-associated increase in IL-17/NF-κB-related module scores. IL-17RA knockdown improved the viability of OGD-exposed SH-SY5Y cells. In MCAO rats, CSP improved neurological and behavioral outcomes, increased cerebral blood flow, and reduced cerebral edema, infarct volume, neuronal loss, microglial responses, and IL-17A/IL-17RA expression. In OGD-exposed BV-2 cells, CSP reduced IL-17A, IL-17RA, NF-κB activator 1 (ACT1), tumor necrosis factor receptor-associated factor 6 (TRAF6), IL-1β, IL-6, and the phosphorylated p65/total p65 ratio. These findings suggest that the protective effects of CSP in ischemic stroke models are associated with attenuation of IL-17/NF-κB-related neuroinflammation.

  • Open Access

    Cordyceps Polysaccharides Attenuate Post-Ischemic Inflammatory Damage in a Rat Stroke Model with Associated Modulation of the mtDNA/NLRP3 Inflammasome-Related Pyroptosis Pathway

    by Yifan Chen, Huizhang Wang, Cong Gai, Xia Li, Yutong Li, Yihui Ma, Huiming Qi, Changhua Shi, Yibo Tang

    Background: Cordyceps polysaccharides (CSP) have shown neuroprotective potential in models of ischemic stroke, but the underlying mechanisms remain to be clarified. Methods: In this study, the effects of CSP were evaluated in MCAO rats and OGD-exposed BV-2 cells. Results: CSP significantly attenuated ischemic injury and inflammatory responses in both in vivo and in vitro models. Mechanistically, CSP decreased CMPK2 expression, increased TFAM levels, and reduced 8-OHdG expression, suggesting attenuation of oxidative DNA damage and mitochondrial DNA-associated stress. EdU staining further showed that OGD-induced DNA synthesis-related signals were predominantly extranuclear, supporting the possibility of mtDNA-associated alterations under ischemia-like conditions. Moreover, CSP suppressed the upregulation of NLRP3, Caspase-1, N-GSDMD, IL-1β, and IL-18, and reduced LDH release following OGD exposure, suggesting inhibition of inflammasome-associated pyroptotic signaling. Conclusions: These findings suggest that the neuroprotective effects of CSP in ischemic stroke models may be related to the modulation of CMPK2/mtDNA/NLRP3 inflammasome pathway and reduced pyroptosis.


  • The effects of Cordyceps polysaccharides on ischemic brain injury in rats via intervening with IL-23/IL-17 axis and the intestinal barrier

    by Yang Jiang, Yan Liao, Zhenquan Liu, Manyu Zhou, Huizhang Wang, Huiming Qi, Shuyong Sun, Saiwen Xi, Yibo Tang


  • The role of IL-23/IL-17 axis in ischemic stroke from the perspective of gut-brain axis

    by Yang Jiang, Yajie Dai, Zhenquan Liu, Yan Liao, Shuyong Sun, Xianghe Kong, Jingjing Hu, Yibo Tang


  • Open Access

    Ischemic stroke: From pathological mechanisms to neuroprotective strategies

    by Yang Jiang, Zhenquan Liu, Yan Liao, Shuyong Sun, Yajie Dai, Yibo Tang

    Ischemic stroke (IS) has complex pathological mechanisms, and is extremely difficult to treat. At present, the treatment of IS is mainly based on intravenous thrombolysis and mechanical thrombectomy, but they are limited by a strict time window. In addition, after intravenous thrombolysis or mechanical thrombectomy, damaged neurons often fail to make ideal improvements due to microcirculation disorders. Therefore, finding suitable pathways and targets from the pathological mechanism is crucial for the development of neuroprotective agents against IS. With the hope of making contributions to the development of IS treatments, this review will introduce (1) how related targets are found in pathological mechanisms such as inflammation, excitotoxicity, oxidative stress, and complement system activation; and (2) the current status and challenges in drug development.